Skip to main content
Fig. 3 | BMC Cardiovascular Disorders

Fig. 3

From: Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a “real world” STEMI population: results from the Italian “CARDIO-STEMI SANREMO” registry

Fig. 3

Kaplan–Meier analysis of follow-up survival for (a) PG-l and (b) non-PG-l patients, stratified by ticagrelor prescription at discharge. The table shows the number of patients on ticagrelor versus no ticagrelor at discharge. Abbreviation: PG-l = PEGASUS-TIMI 54-like patients

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us